| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreaticoduodenectomy | 12 | 2022 | 106 | 2.790 |
Why?
|
| Pancreatic Neoplasms | 23 | 2025 | 739 | 2.520 |
Why?
|
| Drainage | 9 | 2021 | 264 | 2.030 |
Why?
|
| Carcinoma, Pancreatic Ductal | 13 | 2025 | 169 | 1.960 |
Why?
|
| Pancreatic Fistula | 5 | 2021 | 30 | 1.650 |
Why?
|
| Postoperative Care | 4 | 2019 | 311 | 1.340 |
Why?
|
| Pancreatectomy | 11 | 2025 | 151 | 1.270 |
Why?
|
| Postoperative Complications | 12 | 2025 | 3171 | 1.210 |
Why?
|
| Pancreas | 4 | 2023 | 231 | 0.840 |
Why?
|
| Adenocarcinoma | 7 | 2023 | 1013 | 0.690 |
Why?
|
| Pancreatitis | 1 | 2020 | 144 | 0.620 |
Why?
|
| Pancreatitis, Chronic | 4 | 2025 | 76 | 0.620 |
Why?
|
| Choristoma | 1 | 2018 | 46 | 0.600 |
Why?
|
| Pancreatic Diseases | 1 | 2018 | 40 | 0.590 |
Why?
|
| Incidental Findings | 1 | 2018 | 128 | 0.560 |
Why?
|
| Spleen | 1 | 2018 | 286 | 0.560 |
Why?
|
| Clinical Protocols | 1 | 2018 | 245 | 0.550 |
Why?
|
| Nutritional Support | 1 | 2017 | 57 | 0.510 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 139 | 0.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 1351 | 0.440 |
Why?
|
| Colorectal Neoplasms | 7 | 2009 | 638 | 0.440 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2008 | 445 | 0.420 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 822 | 0.390 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 2009 | 60 | 0.380 |
Why?
|
| Pancreatic Cyst | 2 | 2019 | 28 | 0.310 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2009 | 25 | 0.310 |
Why?
|
| Humans | 52 | 2025 | 133271 | 0.310 |
Why?
|
| Neoplasm Transplantation | 3 | 2021 | 399 | 0.310 |
Why?
|
| Neovascularization, Pathologic | 2 | 2008 | 259 | 0.300 |
Why?
|
| Quality of Life | 4 | 2025 | 2165 | 0.300 |
Why?
|
| ErbB Receptors | 2 | 2019 | 302 | 0.290 |
Why?
|
| Liver Regeneration | 1 | 2008 | 41 | 0.290 |
Why?
|
| Jejunal Diseases | 1 | 2007 | 15 | 0.280 |
Why?
|
| Health Status Disparities | 2 | 2025 | 252 | 0.280 |
Why?
|
| Prospective Studies | 8 | 2020 | 6582 | 0.280 |
Why?
|
| Ileal Neoplasms | 1 | 2007 | 7 | 0.280 |
Why?
|
| Carcinoid Tumor | 1 | 2007 | 24 | 0.270 |
Why?
|
| Aged | 18 | 2025 | 21476 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1310 | 0.260 |
Why?
|
| Intestinal Obstruction | 1 | 2007 | 96 | 0.250 |
Why?
|
| Middle Aged | 20 | 2025 | 28952 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 1049 | 0.250 |
Why?
|
| Cell Proliferation | 8 | 2019 | 2559 | 0.250 |
Why?
|
| Male | 26 | 2025 | 65523 | 0.240 |
Why?
|
| Precancerous Conditions | 2 | 2019 | 254 | 0.220 |
Why?
|
| Retrospective Studies | 11 | 2022 | 17556 | 0.220 |
Why?
|
| Female | 24 | 2025 | 71439 | 0.210 |
Why?
|
| Anastomosis, Surgical | 2 | 2021 | 167 | 0.210 |
Why?
|
| Nitric Oxide | 1 | 2006 | 487 | 0.200 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2008 | 103 | 0.200 |
Why?
|
| Mass Spectrometry | 2 | 2021 | 367 | 0.200 |
Why?
|
| RNA, Small Interfering | 3 | 2018 | 720 | 0.200 |
Why?
|
| Tumor Microenvironment | 2 | 2025 | 699 | 0.200 |
Why?
|
| Clinical Decision-Making | 1 | 2025 | 300 | 0.200 |
Why?
|
| Cell Line, Tumor | 9 | 2019 | 3794 | 0.190 |
Why?
|
| Laparoscopy | 2 | 2020 | 520 | 0.190 |
Why?
|
| Amylases | 2 | 2019 | 24 | 0.180 |
Why?
|
| Cancer Vaccines | 1 | 2023 | 190 | 0.180 |
Why?
|
| Biomedical Technology | 1 | 2021 | 37 | 0.180 |
Why?
|
| Margins of Excision | 1 | 2021 | 59 | 0.180 |
Why?
|
| Heterografts | 1 | 2021 | 201 | 0.170 |
Why?
|
| Liver | 1 | 2008 | 1859 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 829 | 0.170 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 5436 | 0.160 |
Why?
|
| Mice, Nude | 3 | 2018 | 780 | 0.160 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 1849 | 0.160 |
Why?
|
| Cystadenoma, Serous | 1 | 2019 | 7 | 0.160 |
Why?
|
| Pleural Neoplasms | 1 | 2020 | 81 | 0.160 |
Why?
|
| Immunotherapy | 2 | 2023 | 750 | 0.160 |
Why?
|
| Device Removal | 2 | 2018 | 223 | 0.160 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2019 | 27 | 0.150 |
Why?
|
| Cell Movement | 6 | 2018 | 906 | 0.150 |
Why?
|
| Neoplasms | 2 | 2021 | 2984 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2025 | 788 | 0.150 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2019 | 74 | 0.150 |
Why?
|
| Preservation, Biological | 1 | 2018 | 10 | 0.150 |
Why?
|
| RNAi Therapeutics | 1 | 2018 | 18 | 0.150 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 357 | 0.150 |
Why?
|
| Pathologists | 1 | 2018 | 27 | 0.150 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 312 | 0.150 |
Why?
|
| Semaphorins | 2 | 2016 | 33 | 0.150 |
Why?
|
| Neuropilin-2 | 2 | 2008 | 9 | 0.150 |
Why?
|
| GPI-Linked Proteins | 1 | 2019 | 108 | 0.150 |
Why?
|
| Nutritional Status | 2 | 2019 | 328 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1965 | 0.150 |
Why?
|
| Radiologists | 1 | 2018 | 51 | 0.150 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 520 | 0.150 |
Why?
|
| Adult | 9 | 2025 | 31650 | 0.150 |
Why?
|
| Biological Specimen Banks | 1 | 2018 | 55 | 0.140 |
Why?
|
| Mesenteric Veins | 1 | 2018 | 13 | 0.140 |
Why?
|
| Clinical Enzyme Tests | 1 | 2018 | 16 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 1013 | 0.140 |
Why?
|
| Specimen Handling | 1 | 2018 | 144 | 0.140 |
Why?
|
| Random Allocation | 2 | 2009 | 443 | 0.140 |
Why?
|
| Organoplatinum Compounds | 2 | 2008 | 33 | 0.140 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 202 | 0.130 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 13 | 0.130 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 1363 | 0.130 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 116 | 0.130 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 1307 | 0.130 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2018 | 351 | 0.130 |
Why?
|
| Venous Thrombosis | 1 | 2018 | 173 | 0.120 |
Why?
|
| Transplantation, Heterologous | 3 | 2021 | 276 | 0.120 |
Why?
|
| Treatment Outcome | 9 | 2019 | 13102 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 211 | 0.120 |
Why?
|
| Duodenal Neoplasms | 1 | 2016 | 24 | 0.120 |
Why?
|
| Risk Factors | 6 | 2021 | 10956 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2016 | 59 | 0.120 |
Why?
|
| Mice | 9 | 2023 | 18929 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2018 | 1240 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 1214 | 0.120 |
Why?
|
| Lymph Nodes | 1 | 2017 | 395 | 0.120 |
Why?
|
| Animals | 12 | 2023 | 36195 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 679 | 0.110 |
Why?
|
| Incidence | 4 | 2019 | 3391 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 206 | 0.110 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 18 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2018 | 578 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2021 | 3719 | 0.110 |
Why?
|
| Surgeons | 1 | 2018 | 285 | 0.110 |
Why?
|
| Malnutrition | 1 | 2017 | 222 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 5 | 2018 | 674 | 0.110 |
Why?
|
| Bile Duct Diseases | 1 | 2013 | 17 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2191 | 0.100 |
Why?
|
| Bile | 1 | 2013 | 47 | 0.100 |
Why?
|
| Deoxycytidine | 1 | 2013 | 84 | 0.100 |
Why?
|
| Bevacizumab | 1 | 2013 | 80 | 0.100 |
Why?
|
| Radiotherapy Dosage | 1 | 2013 | 232 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 874 | 0.100 |
Why?
|
| Remission Induction | 1 | 2013 | 307 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2014 | 245 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 772 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2019 | 1139 | 0.100 |
Why?
|
| Length of Stay | 2 | 2018 | 1394 | 0.090 |
Why?
|
| Erythrocyte Transfusion | 1 | 2013 | 135 | 0.090 |
Why?
|
| Gastroenterology | 1 | 2014 | 205 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2013 | 373 | 0.090 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 273 | 0.090 |
Why?
|
| Biomarkers | 2 | 2018 | 3418 | 0.080 |
Why?
|
| Mutation | 3 | 2025 | 6341 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 484 | 0.080 |
Why?
|
| Medically Uninsured | 1 | 2010 | 76 | 0.080 |
Why?
|
| Prognosis | 2 | 2023 | 5042 | 0.080 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2008 | 3 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 555 | 0.070 |
Why?
|
| Liver Neoplasms | 2 | 2010 | 1408 | 0.070 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2009 | 96 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 2125 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 1 | 2008 | 74 | 0.070 |
Why?
|
| Survival Rate | 1 | 2013 | 2208 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2023 | 965 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 2144 | 0.070 |
Why?
|
| Hepatectomy | 1 | 2008 | 124 | 0.070 |
Why?
|
| Jejunum | 1 | 2007 | 130 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2007 | 82 | 0.070 |
Why?
|
| Constriction, Pathologic | 1 | 2007 | 238 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 398 | 0.060 |
Why?
|
| Serotonin | 1 | 2007 | 222 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2009 | 351 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2006 | 177 | 0.060 |
Why?
|
| Mesoderm | 1 | 2006 | 113 | 0.060 |
Why?
|
| Signal Transduction | 6 | 2019 | 4915 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2016 | 2719 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 3105 | 0.060 |
Why?
|
| Epithelium | 1 | 2006 | 354 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 1083 | 0.060 |
Why?
|
| Registries | 3 | 2019 | 1582 | 0.060 |
Why?
|
| Tissue Array Analysis | 1 | 2025 | 143 | 0.060 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 591 | 0.060 |
Why?
|
| Frozen Sections | 1 | 2023 | 31 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2018 | 1584 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 2 | 2017 | 404 | 0.050 |
Why?
|
| 5'-Nucleotidase | 1 | 2023 | 21 | 0.050 |
Why?
|
| Observer Variation | 1 | 2023 | 309 | 0.050 |
Why?
|
| Time Factors | 3 | 2019 | 6545 | 0.050 |
Why?
|
| Adenosine | 1 | 2023 | 139 | 0.050 |
Why?
|
| Cell Survival | 2 | 2019 | 884 | 0.050 |
Why?
|
| Common Bile Duct | 1 | 2021 | 15 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2576 | 0.040 |
Why?
|
| Parathyroidectomy | 1 | 2021 | 48 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 1001 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2021 | 120 | 0.040 |
Why?
|
| Thyroid Gland | 1 | 2021 | 117 | 0.040 |
Why?
|
| Interleukin-15 | 1 | 2021 | 96 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2021 | 256 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 2288 | 0.040 |
Why?
|
| Bone Morphogenetic Protein 3 | 1 | 2019 | 1 | 0.040 |
Why?
|
| Cyst Fluid | 1 | 2019 | 6 | 0.040 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2019 | 21 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2008 | 1730 | 0.040 |
Why?
|
| Cetuximab | 1 | 2019 | 14 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 391 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2019 | 59 | 0.040 |
Why?
|
| T-Box Domain Proteins | 1 | 2019 | 124 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 306 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 177 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2018 | 5196 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 168 | 0.040 |
Why?
|
| Pyridones | 1 | 2019 | 130 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2018 | 256 | 0.030 |
Why?
|
| Immunoprecipitation | 2 | 2008 | 206 | 0.030 |
Why?
|
| Vascular Patency | 1 | 2018 | 198 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 214 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 614 | 0.030 |
Why?
|
| Apoptosis | 3 | 2009 | 1928 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 1097 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2018 | 158 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 279 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2021 | 1185 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2019 | 619 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 176 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2019 | 689 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 149 | 0.030 |
Why?
|
| Ampulla of Vater | 1 | 2016 | 16 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2019 | 361 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 449 | 0.030 |
Why?
|
| Insulin | 1 | 2021 | 1245 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 1582 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2016 | 238 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 322 | 0.030 |
Why?
|
| Proteomics | 1 | 2019 | 604 | 0.030 |
Why?
|
| Reoperation | 1 | 2018 | 856 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2016 | 245 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2018 | 431 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 2141 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1471 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 179 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 2013 | 134 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1100 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 3986 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2018 | 551 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 3046 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 129 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2013 | 321 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 748 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 407 | 0.020 |
Why?
|
| Base Sequence | 1 | 2016 | 3153 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2013 | 212 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2014 | 361 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2016 | 3960 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 4755 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 734 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 414 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 937 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2009 | 45 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2009 | 37 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 7138 | 0.020 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2008 | 36 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2009 | 68 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2008 | 7 | 0.020 |
Why?
|
| Autoradiography | 1 | 2008 | 73 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2008 | 10 | 0.020 |
Why?
|
| Jagged-1 Protein | 1 | 2008 | 53 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2009 | 141 | 0.020 |
Why?
|
| Pregnancy Proteins | 1 | 2008 | 14 | 0.020 |
Why?
|
| Placenta Growth Factor | 1 | 2008 | 15 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2008 | 85 | 0.020 |
Why?
|
| Half-Life | 1 | 2008 | 162 | 0.020 |
Why?
|
| Neuropilin-1 | 1 | 2007 | 16 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2008 | 63 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 103 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2008 | 45 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2008 | 316 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 334 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 1136 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 297 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2009 | 441 | 0.020 |
Why?
|
| Liposomes | 1 | 2008 | 207 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2009 | 381 | 0.020 |
Why?
|
| Spindle Apparatus | 1 | 2006 | 50 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 1136 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2008 | 814 | 0.020 |
Why?
|
| Hepatitis C, Chronic | 1 | 2010 | 371 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 1095 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 910 | 0.010 |
Why?
|
| Cadherins | 1 | 2006 | 183 | 0.010 |
Why?
|
| Peptides | 1 | 2009 | 863 | 0.010 |
Why?
|
| Carcinoma | 1 | 2008 | 305 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 511 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 1325 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 741 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 1757 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 2876 | 0.010 |
Why?
|
| Texas | 1 | 2010 | 3664 | 0.010 |
Why?
|
| Disease Progression | 1 | 2008 | 2246 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2008 | 1610 | 0.010 |
Why?
|
| United States | 1 | 2015 | 11723 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 4577 | 0.010 |
Why?
|
| Child | 1 | 2018 | 25851 | 0.010 |
Why?
|